Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 21, 2016; 22(47): 10406-10414
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10406
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10406
Table 1 Patient, tumor, and treatment characteristics patients treated (n = 34)
n (%) | ||
FDG avidity | Yes | 19 (56) |
No | 15 (44) | |
ECOG-PS1 | 0 | 17 (50) |
1 | 14 (41) | |
≥ 2 | 3 (9) | |
Gender | Female | 9 (27) |
Male | 25 (74) | |
Grade | G1 | 18 (53) |
G2 | 6 (18) | |
G3 | 1 (3) | |
Unknown | 9 (27) | |
Presence of cirrhosis | 20 (59) | |
Causes of cirrhosis (n = 20) | Viral hepatitis | 12 (60) |
Hepatitis B | 2 (10) | |
Hepatitis C | 10 (50) | |
Alcohol | 4 (20) | |
NASH2 | 4 (20) | |
Prior treatment | 15 (44) | |
Child pugh class | A | 31 (91) |
B | 3 (9) | |
BCLC stage3 | A | 4 (12) |
B | 10 (29) | |
C | 19 (56) | |
D | 1 (3) | |
Tumor burden4 | ≤ 50% | 29 (85) |
> 50% | 5 (15) | |
Portal vein thrombosis | 5 (15) | |
Extrahepatic disease | 3 (9) | |
Median (Range) | ||
Age | 68 (46-84) | |
PET SUVmax | 4 (2-20) | |
Initial AFP | 14 (1-186000) | |
Volume treated (mL) | 1146 (191-2340) | |
Dose delivered (Gy) | 126.6 (110.5-478.6) | |
Follow up (mo) | 12 (1-63) |
- Citation: Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol 2016; 22(47): 10406-10414
- URL: https://www.wjgnet.com/1007-9327/full/v22/i47/10406.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i47.10406